Amber Campbell, DO
General Practice · Warsaw, MONPI 1689804437
Payments from drug & device makers
Across 119 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$336
- Sunovion Pharmaceuticals Inc.$242
- AbbVie$228
- Novo Nordisk$162
- Sanofi-aventis U.S. LLC$123
- Amgen$99
- plus $744 from 20 others
What the payments were for
- Food & beverage$1,92299%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $336 |
| Sunovion Pharmaceuticals Inc. | 14 | $242 |
| AbbVie(2 entities) | 12 | $228 |
| Novo Nordisk | 10 | $162 |
| Sanofi-aventis U.S. LLC | 11 | $123 |
| Amgen | 7 | $99 |
| Pfizer | 7 | $98 |
| Boehringer Ingelheim | 5 | $83 |
| Merck | 5 | $76 |
| Novartis | 4 | $61 |
| Lilly USA, LLC | 4 | $54 |
| Astellas Pharma US Inc | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Abbott | 2 | $38 |
| Exact Sciences | 2 | $33 |
| Organon | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $29 |
| GSK | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
How this compares
$1,935 in reported general payments places this provider in the 90th percentile of 1,446 general practice providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnbrelEtanercept | 14 | $196,904 |
| OzempicSemaglutide | 126 | $142,518 |
| TrulicityDulaglutide | 69 | $84,780 |
| JardianceEmpagliflozin | 101 | $76,099 |
| XareltoRivaroxaban | 84 | $69,533 |
| EliquisApixaban | 75 | $57,759 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $49,161 |
| MyrbetriqMirabegron | 69 | $42,647 |
| LinzessLinaclotide | 61 | $39,699 |
| Repatha SureclickEvolocumab | 45 | $38,036 |
| RybelsusSemaglutide | 33 | $34,796 |
| RexultiBrexpiprazole | 22 | $33,275 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $27,057 |
| Spiriva RespimatTiotropium Bromide | 38 | $22,757 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $18,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $99 | $196,90414 claims |
| Novo NordiskOzempic, Rybelsus | $162 | $177,315159 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $83 | $116,139165 claims |
| Lilly USA, LLCTrulicity | $54 | $84,78069 claims |
| AbbVieLinzess, Namzaric, Vraylar | $228 | $75,05794 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy | $24 | $74,238142 claims |
| Johnson & JohnsonXarelto | $29 | $69,53384 claims |
| PfizerEliquis | $98 | $57,75975 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $42,64769 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $30 | $33,27522 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Brilinta | $336 | $31,03482 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $123 | $27,05727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,446 general practice providers in Missouri.
Other general practice in Warsaw
- Bernard MillerSaint Louis$546K
- Baron GrutterGladstone$445K
- Shuka MoshiriSaint Louis$253K
- Arthur GreenbergKansas City$241K
- Robert CalaluceColumbia$189K
- David HoneycuttMonett$83K
- Suraiya SiddiqueMount Vernon$61K
- John FluckeLees Summit$60K
- Rex HudsonSaint Louis$49K
- David KaelinCape Girardeau$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.